Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | The evolving role of maintenance therapy post-ASCT in MM

Philip McCarthy • 26 Oct 2019
COSTEM 2019
Multiple Myeloma Bortezomib Lenalidomide

Philip McCarthy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, outlines the role of maintenance therapy following autologous stem cell transplantation (ASCT) in multiple myeloma (MM). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Philip McCarthy

4:02
Treatment-free intervals: what is best for patients?
Philip McCarthy • 1 Sep 2021
4:22
Future maintenance therapy approaches for multiple myeloma
Philip McCarthy • 1 Sep 2021
5:15
CAR-T for myeloma: where are we now and where are we going?
Philip McCarthy • 1 Sep 2021
10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al. • 13 Sep 2019

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals